Breakthroughs, Research And Media
|Major Blindness Breakthrough|
|Last updated: 29 April 2008|
therapy for a rare type of inherited blindness has improved the vision
of four patients who tried it, boosting hopes for the troubled field of
gene repair technology, scientists say.
Two separate teams of doctors reported successes in using gene therapy to treat a condition known as Leber congenital amaurosis, or LCA.LCA damages light receptors in the retina. It usually begins affecting sight in early childhood and causes total blindness by the time a patient is 30. There is no treatment.
Both teams used a common cold virus to deliver a normal version of one damaged gene that causes the disease, called RPE65, directly into the eyes of patients.
Dr Katherine High of the Children's Hospital of Philadelphia and the Howard Hughes Medical Institute and colleagues said all three of their volunteers had improved vision after the treatments.
Dr Robin Ali of University College London and colleagues said one of their three volunteers got better.
Because the patients were adults, already had severe sight loss and received only low doses of treatment, researchers had not expected to see a benefit at all.
"This result is important for the entire field of gene therapy," said High, a former president of the American Society of Gene Therapy.
Improvements in night vision
"Now, my sight when it's getting dark or it's badly lit is definitely better. It's a small change - but it makes a big difference to me," Howarth said in a statement.
"The fact we see any evidence of improvement under these circumstances gives great hopes for the effectiveness of the treatment," Ali said in a telephone interview.
In High's trial, three patients aged 19, 26 and 26, all reported better vision.
"Patients' vision improved from detecting hand movements to reading lines on an eye chart," said Dr Albert Maguire of Children's Hospital.
In each case, only one eye was treated, so the other eye could be used as a "control" to tell whether vision improved.
Ali and his team are working on the research with Targeted Genetics Corp, which made the genetically engineered virus. The Children's Hospital and University of Pennsylvania team developed their own virus, called a vector, to carry the corrective gene.
"We are pretty convinced that once we can do this with younger children we will be able to arrest the damage," said Targeted Genetics Chief Executive Stewart Parker.
One important thing both teams were looking for was proof the virus did not leave the eye. "It stays in there. It doesn't go anywhere else," Parker said.
Both safety and efficacy have held back the field of gene therapy. One experiment cured two French boys with a rare immune disorder, but gave them leukaemia in 2002, and an Arizona teenager died in a 1999 gene therapy experiment.
Hope for South Africans
They also said that they are actively seeking young South Africans affected by LCA to check if they have the same gene mutation as the patients in the new studies.
�The gene therapy will only work in a specific gene � the RPE65 gene and not in other LCA genes,� said Claudette Medefindt, Director for Science of Retina South Africa. �Gene tracking is critical to identify all young South Africans who may benefit from this ground breaking trials.�
Retina South Africa funds the gene tracking project at the University of Cape Town and requests that parents of young adults affected by LCA and other retinal degenerative conditions contact them urgently on share call number 0860595959.
� (Reuters Health/Health24)